Citicoline (CDP-choline) increases Sirtuin1 expression concomitant to neuroprotection in experimental stroke

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Citicoline (CDP-choline) demonstrates neuroprotective effects in cerebral ischemia.
• Previous human trials show mixed results, with benefits in specific stroke patient subgroups.
• The precise mechanisms underlying CDP-choline's neuroprotection require further elucidation.

Purpose of the Study:

• To investigate the role of Sirtuin 1 (SIRT1) in the neuroprotective actions of CDP-choline.
• To determine if CDP-choline modulates SIRT1 expression or activity in the context of ischemic stroke.
• To explore potential therapeutic strategies targeting SIRT1 for stroke treatment.

Main Methods:

• Fischer rats and Sirt1 knockout mice were subjected to permanent focal ischemia.
• Administration of CDP-choline, the SIRT1 inhibitor sirtinol, and the SIRT1 activator resveratrol.
• Assessment of infarct volume and Western blot analysis of brain tissue at 24 and 48 hours post-ischemia.

Main Results:

• CDP-choline treatment increased brain SIRT1 protein levels and provided neuroprotection.
• Sirtinol administration blocked the infarct-reducing effect of CDP-choline.
• Resveratrol showed a synergistic neuroprotective effect with CDP-choline.
• CDP-choline did not reduce infarct volume in Sirt1 knockout mice, indicating SIRT1 dependence.

Conclusions:

• CDP-choline acts as a SIRT1 activator, up-regulating its expression to achieve neuroprotection.
• SIRT1 plays a critical role in mediating the beneficial effects of CDP-choline in stroke.
• Targeting SIRT1 activation represents a promising therapeutic avenue for stroke management.